9puy
From Proteopedia
Jump to navigationJump to search
SARS-CoV-2 Papain-like Protease (PLpro) in complex with Fragment 27
| ||||||||||||
Structural highlights
Publication Abstract from PubMedSARS-CoV-2 papain-like protease (PL(Pro)) plays a key role in viral replication and the host immune response and is a promising target for developing new antiviral treatments. We previously reported a fragment-based screen to identify hits that bind to SARS-CoV-2 PL(Pro). Here, we describe the discovery of potent PL(Pro) inhibitors by optimizing one of these hits via extensive medicinal chemistry guided by multiple X-ray structures of cocomplexes. Lead compound 46 is shown to bind to the S3 and S4 pockets with nanomolar affinity (0.4 muM) and exhibits robust cellular activity and resistance to mutation. This novel class of PL(Pro) inhibitors can potentially be used as a starting point for the development of inhibitors to combat the emergence of drug-resistant viral strains and future coronavirus outbreaks. Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PL(Pro).,Wei Q, Taylor AJ, Barmade MA, Teuscher KB, Chowdhury S, Apakama C, Anderson-Daniels J, Yongqing Z, Schultz DC, Rietz TA, South TM, Crow MM, Zhao B, Amporndanai K, Sensintaffar JL, Phan J, Cherry S, Denison M, Lee T, Fesik SW J Med Chem. 2026 Jan 22;69(2):1419-1433. doi: 10.1021/acs.jmedchem.5c02832. Epub , 2026 Jan 11. PMID:41521555[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||||
This page was last modified 13:19, 10 February 2026.